Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC vaccination with standard radiochemotherapy in newly diagnosed glioblastoma
DRKS00013248Phase 2Active, not recruiting
- Sponsor
- Heinrich Heine University Düsseldorf
- Start
- Nov 2017
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of WT1/hTERT/Survivin-loaded dendritic cell vaccine in glioblastoma (GBM) (2 arms), sponsored by Heinrich Heine University Düsseldorf. Started Nov 2017; status: active, not recruiting.
02
Drugs
WT1/hTERT/Survivin-loaded dendritic cell vaccine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on DRKS00013248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00013248.